Identifying Optimal Candidates for Primary Tumor Resection Among Metastatic Pancreatic Cancer Patients: A Population-Based Predictive Model

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155.
   PubMed Web of Science ®Google Scholar
• Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2(1):16022. doi:10.1038/nrdp.2016.22.
   PubMedGoogle Scholar
• He C, Huang X, Zhang Y, Lin X, Li S. The impact of different metastatic patterns on survival in patients with pancreatic cancer. Pancreatology. 2021;21(3):556–563. doi:10.1016/j.pan.2021.01.014.
   PubMed Web of Science ®Google Scholar
• Su BB, Bai DS, Yu JQ, Zhang C, Jin SJ, Zhou BH, et al. Can patients with pancreatic cancer and liver metastases obtain survival benefit from surgery? A population-based study. J Cancer. 2021;12(2):539–552. doi:10.7150/jca.51218.
   PubMed Web of Science ®Google Scholar
• Allendorf JD, Lauerman M, Bill A, DiGiorgi M, Goetz N, Vakiani E, et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg. 2008;12(1):91–100. doi:10.1007/s11605-007-0296-7.
   PubMed Web of Science ®Google Scholar
• Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O’Reilly EM, et al. Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(23):2784–2796. doi:10.1200/JCO.2016.67.1412.
   PubMed Web of Science ®Google Scholar
• Warschkow R, Güller U, Tarantino I, Cerny T, Schmied BM, Thuerlimann B, et al. Improved survival after primary tumor surgery in metastatic breast cancer: a propensity-adjusted, population-based SEER trend analysis. Ann Surg. 2016;263(6):1188–1198. doi:10.1097/SLA.0000000000001302.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–1659. doi:10.1056/NEJMoa003013.
   PubMed Web of Science ®Google Scholar
• Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000;135(5):530–534. doi:10.1001/archsurg.135.5.530.
   PubMedGoogle Scholar
• Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67(1):3–6. doi:10.1016/j.eururo.2014.08.056.
   PubMed Web of Science ®Google Scholar
• Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–1066. doi:10.1016/j.eururo.2013.11.012.
   PubMed Web of Science ®Google Scholar
• Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14(1):118–127. doi:10.1245/s10434-006-9131-8.
   PubMed Web of Science ®Google Scholar
• Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136–144. doi:10.1016/j.surg.2016.02.019.
   PubMed Web of Science ®Google Scholar
• Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11–26. doi:10.1038/s41571-018-0112-1.
   PubMed Web of Science ®Google Scholar
• McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, et al. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg. 2007;246(2):246–253. doi:10.1097/01.sla.0000259993.17350.3a.
   PubMed Web of Science ®Google Scholar
• Hackert T, Büchler MW. Pancreatic cancer: advances in treatment, results and limitations. Dig Dis. 2013;31(1):51–56. doi:10.1159/000347178.
   PubMed Web of Science ®Google Scholar
• Seelig SK, Burkert B, Chromik AM, Tannapfel A, Uhl W, Seelig MH. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy. HPB Surg. 2010;2010:579672–579676. doi:10.1155/2010/579672.
   PubMedGoogle Scholar
• Singh A, Singh T, Chaudhary A. Synchronous resection of solitary liver metastases with pancreaticoduodenectomy. JOP. 2010;11(5):434–438.
   PubMedGoogle Scholar
• Lemke J, Barth TF, Juchems M, Kapapa T, Henne-Bruns D, Kornmann M. Long-term survival following resection of brain metastases from pancreatic cancer. Anticancer Res. 2011;31(12):4599–4603.
   PubMed Web of Science ®Google Scholar
• Dünschede F, Will L, von Langsdorf C, Möhler M, Galle PR, Otto G, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res. 2010;44(3–4):209–213. doi:10.1159/000313532.
   PubMed Web of Science ®Google Scholar
• Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484–2492. doi:10.1002/cncr.23074.
   PubMed Web of Science ®Google Scholar
• Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–589. doi:10.1001/jamasurg.2018.0501.
   PubMed Web of Science ®Google Scholar
• McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9(4):403–425. doi:10.1037/1082-989X.9.4.403.
   PubMed Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107. doi:10.1002/sim.3697.
   PubMed Web of Science ®Google Scholar
• Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17(1):1. doi:10.6004/jnccn.2019.0003.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Behrman SW, Benson AB, 3rd, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083–1093. doi:10.6004/jnccn.2014.0106.
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Seufferlein T. Systemic therapy for metastatic pancreatic cancer. Curr Treat Options Oncol. 2021;22(11):106. doi:10.1007/s11864-021-00895-4.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang L, Chen L, Chen Z. Do patients diagnosed with metastatic pancreatic cancer benefit from primary tumor surgery? A propensity-adjusted, population-based surveillance, epidemiology and end results (SEER) analysis. Med Sci Monit. 2019;25:8230–8241. doi:10.12659/MSM.917106.
   PubMed Web of Science ®Google Scholar
• McKenzie S, Mailey B, Artinyan A, Kim J, Ellenhorn JD. The incidence and outcomes of pancreatectomy in patients with metastatic pancreatic adenocarcinoma. JOP. 2010;11(4):341–347.
   PubMedGoogle Scholar
• Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476–1484. doi:10.1136/gutjnl-2015-309304.
   PubMed Web of Science ®Google Scholar
• Weniger M, Honselmann KC, Liss AS. The extracellular matrix and pancreatic cancer: a complex relationship. Cancers (Basel). 2018;10(9):316. doi:10.3390/cancers10090316.
   PubMed Web of Science ®Google Scholar
• Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–2211. doi:10.1158/0008-5472.can-03-2646.
   PubMed Web of Science ®Google Scholar
• Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, Massagué J. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–1326. doi:10.1016/j.cell.2009.11.025.
   PubMed Web of Science ®Google Scholar
• Comen E, Norton L, Massagué J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369–377. doi:10.1038/nrclinonc.2011.64.
   PubMed Web of Science ®Google Scholar
• Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105–117. doi:10.1016/j.bbcan.2009.11.002.
   PubMed Web of Science ®Google Scholar
• Rochefort MM, Ankeny JS, Kadera BE, Donald GW, Isacoff W, Wainberg ZA, et al. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol. 2013;20(13):4322–4329. doi:10.1245/s10434-013-3159-3.
   PubMed Web of Science ®Google Scholar
• Wu H, Guo JC, Yang SH, Tien YW, Kuo SH. Postoperative imaging and tumor marker surveillance in resected pancreatic cancer. J Clin Med. 2019;8(8):1115. doi:10.3390/jcm8081115.
   PubMed Web of Science ®Google Scholar
• Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, et al. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? Surgery. 2012;152(1):S112–S119. doi:10.1016/j.surg.2012.05.017.
   PubMedGoogle Scholar
• Mizuno N, Hara K, Hijioka S, Bhatia V, Shimizu Y, Yatabe Y, et al. Current concept of endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Pancreatology. 2011;11(2):40–46. doi:10.1159/000323502.
   PubMedGoogle Scholar
• Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237(1):74–85. doi:10.1097/00000658-200301000-00011.
   PubMed Web of Science ®Google Scholar
• Takahashi C, Shridhar R, Huston J, Meredith K. Correlation of tumor size and survival in pancreatic cancer. J Gastrointest Oncol. 2018;9(5):910–921. doi:10.21037/jgo.2018.08.06.
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang X, Tian Y, Aimaiti S, Zhang J, Zhao J, et al. Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China. PeerJ. 2018;6:e4893. doi:10.7717/peerj.4893.
   PubMed Web of Science ®Google Scholar
• Li D, Hu B, Zhou Y, Wan T, Si X. Impact of tumor size on survival of patients with resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):985. doi:10.1186/s12885-018-4901-9.
   PubMedGoogle Scholar
• Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, et al. Multi-institutional validation study of the American Joint Commission on Cancer (8th Edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 2017;265(1):185–191. doi:10.1097/SLA.0000000000001763.
   PubMed Web of Science ®Google Scholar
• Han SH, Heo JS, Choi SH, Choi DW, Han IW, Han S, et al. Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection. Int J Surg. 2017;40:68–72. doi:10.1016/j.ijsu.2017.02.007.
   PubMed Web of Science ®Google Scholar